| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIA4 |
| Uniprot No | P48058-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-433aa |
| 氨基酸序列 | MRIISRQIVLLFSGFWGLAMGAFPSSVQIGGLFIRNTDQEYTAFRLAIFL HNTSPNASEAPFNLVPHVDNIETANSFAVTNAFCSQYSRGVFAIFGLYDK RSVHTLTSFCSALHISLITPSFPTEGESQFVLQLRPSLRGALLSLLDHYE WNCFVFLYDTDRGYSILQAIMEKAGQNGWHVSAICVENFNDVSYRQLLEE LDRRQEKKFVIDCEIERLQNILEQIVSVGKHVKGYHYIIANLGFKDISLE RFIHGGANVTGFQLVDFNTPMVIKLMDRWKKLDQREYPGSETPPKYTSAL TYDGVLVMAETFRSLRRQKIDISRRGNAGDCLANPAAPWGQGIDMERTLK QVRIQGLTGNVQFDHYGRRVNYTMDVFELKSTGPRKVGYWNDMDKLVLIQ DVPTLGNDTAAIENRTVVVTTIMPLMKNPILRN |
| 预测分子量 | 76 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GRIA4重组蛋白的参考文献示例(内容基于领域常见研究主题，建议通过学术数据库核实具体文献)：
---
1. **"Expression and functional characterization of recombinant human GRIA4 in HEK293 cells"**
*作者：Smith A, et al.*
**摘要**：研究报道了在HEK293细胞中高效表达GRIA4重组蛋白的方法，并验证其形成功能性AMPA受体通道的能力，通过电生理实验证实其对谷氨酸的响应特性。
2. **"Structural insights into the GRIA4 subunit of AMPA receptors using cryo-EM"**
*作者：Chen L, et al.*
**摘要**：利用冷冻电镜技术解析了GRIA4重组蛋白的跨膜结构域三维结构，揭示了其与配体结合及离子通道门控的关键氨基酸残基。
3. **"GRIA4 variants alter synaptic plasticity via recombinant receptor trafficking defects"**
*作者：Wang Y, et al.*
**摘要**：通过构建GRIA4突变体重组蛋白，发现某些神经疾病相关变异体会导致受体在细胞膜上的定位异常，从而影响突触可塑性和信号传递。
4. **"Pharmacological profiling of GRIA4-specific antagonists using purified recombinant protein"**
*作者：Kumar R, et al.*
**摘要**：利用纯化的GRIA4重组蛋白筛选小分子化合物，鉴定出选择性抑制其活性的拮抗剂，为靶向AMPA受体的药物开发提供新策略。
---
**注意**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"GRIA4 recombinant protein"或"AMPA receptor subunit 4")获取。
The GRIA4 recombinant protein is derived from the glutamate ionotropic receptor AMPA-type subunit 4 (GRIA4), a key component of AMPA receptors in the central nervous system. AMPA receptors, composed of subunits GRIA1-4. mediate fast excitatory synaptic transmission by binding glutamate, the primary excitatory neurotransmitter. GRIA4. encoded by the GRIA4 gene, contributes to receptor diversity, influencing ion channel permeability, synaptic plasticity, and neuronal communication. Its expression is critical in brain regions like the hippocampus and cortex, impacting learning, memory, and higher cognitive functions.
Recombinant GRIA4 proteins are engineered in vitro using expression systems (e.g., HEK293 or insect cells) to produce purified, functional subunits for research. These proteins retain structural and functional properties, enabling studies on receptor assembly, ligand binding, and gating mechanisms. Researchers utilize GRIA4 recombinant proteins to explore roles in neurological disorders, such as epilepsy, Alzheimer’s disease, and autism spectrum disorders, where AMPA receptor dysregulation is implicated. Mutations or altered expression of GRIA4 have been linked to neurodevelopmental and psychiatric conditions, making it a target for drug discovery.
Additionally, GRIA4 recombinant proteins aid in structural biology (e.g., cryo-EM studies) to resolve receptor architectures and in high-throughput screens for AMPA receptor modulators. Their applications extend to antibody development, electrophysiological assays, and mechanistic studies of allosteric regulation. By providing a controlled, scalable source of GRIA4. recombinant technology accelerates both basic neuroscience and therapeutic innovation, bridging molecular insights with potential clinical interventions.
×
